betaine and Recrudescence

betaine has been researched along with Recrudescence in 3 studies

glycine betaine : The amino acid betaine derived from glycine.

Research

Studies (3)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

A Combination of All-cause Mortality and Major Disability at the 3-month Post-treatment Follow-up.

Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 3 months after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death (NCT01840072)
Timeframe: 3 months

A Combination of Death Within 14 Days After Randomization and Major Disability at 14 Days or at Hospital Discharge if Earlier Than 14 Days.

Major disability was defined as a score of 3 to 5 on the modified Rankin Scale at 14 days after randomization. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. (NCT01840072)
Timeframe: 2 weeks

Cognitive Function (Montreal Cognitive Assessment)

Cognitive function was measured by Montreal Cognitive Assessment at 3 months after randomization. The MoCA is a 30-item test that evaluates the following seven cognitive domains: visuospatial/executive functions, naming, memory, attention, language, abstraction, and orientation. One point is added for participants with education <12 years. Scores on the MoCA range from 0 to 30 and cognitive impairment was defined as a score of <26. (NCT01840072)
Timeframe: Three months

Cognitive Function (the Mini-Mental State Examination)

Cognitive function was measured by the Mini-Mental State Examination at 3 months after randomization. The MMSE contains 20 items that test cognitive performance in domains including orientation, registration, attention and calculation, recall, language, and visual construction. MMSE scores were divided into three ordinal categories: 24-30 (no cognitive impairment), 19-23 (mild cognitive impairment), and 0-17 (severe cognitive impairment). (NCT01840072)
Timeframe: Three months

Long-term Neurological and Functional Status

Those patients who were still alive at hospital discharge were contacted by telephone to set up a follow-up clinical visit. Neurological function was assessed by the modified Rankin scale at the 3-month post-treatment follow-up visit. Scores on the modified Rankin Scale range from 0 to 6, with a score of 0 indicating no symptoms; a score of 5 indicating severe disability (ie, bedridden, incontinent, or requiring constant nursing care and attention); and a score of 6 indicating death. Major disability was defined as a score of 3 to 5 on the modified Rankin Scale. (NCT01840072)
Timeframe: Three months

Mortality

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information on clinical deaths will be obtained. (NCT01840072)
Timeframe: 3 months

Other Vascular Events

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of vascular events, such as myocardial infarction, will be collected. (NCT01840072)
Timeframe: 3 months

Recurrent Stroke

Those patients who are still alive at hospital discharge will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent stroke will be collected. (NCT01840072)
Timeframe: 3 months

Trials

1 trial available for betaine and Recrudescence

Other Studies

2 other studies available for betaine and Recrudescence